Company news
Polaryx Therapeutics, Inc. (NASDAQ:PLYX) news
Polaryx Therapeutics, Inc. news releases on 6ix. Latest, Sep 1, 2026: Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer
Press releases & updates
Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer
September 1, 2026
Polaryx Therapeutics Advances Operational Readiness for SOTERIA Phase 2 Basket Trial
August 25, 2026
Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial
May 28, 2026
Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference
April 23, 2026
Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial
April 21, 2026
Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care
April 15, 2026
Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference
March 31, 2026
Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)
March 16, 2026
Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events
March 11, 2026
Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders
February 26, 2026
Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial
February 16, 2026
Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™
February 9, 2026
Polaryx Therapeutics Welcomes New Members of the Board of Directors
February 4, 2026
Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch
February 2, 2026
Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol “PLYX”
February 1, 2026
Polaryx Therapeutics Announces Approval to List Common Stock on Nasdaq
January 30, 2026